Anti-PRO335 antibodies

US7557192B2 · kind B2 · utility

Assignee

• Genentech, Inc. · US

Inventors

• Avi Ashkenazi · San Mateo, US
• David Botstein · Belmont, US
• Luc Desnoyers · San Francisco, US
• Dan Eaton · San Rafael, US
• Napoleone Ferrara · San Francisco, US
• Ellen Filvaroff · San Francisco, US
• Sherman Fong · Alameda, US
• Wei Gao · Rockville, US
• Hanspeter Gerber · San Francisco, US
• Mary Gerritsen · San Mateo, US
• Audrey Goddard · San Francisco, US
• Paul Godowski · Hillsborough, US
• J. Christopher Grimaldi · San Francisco, US
• Austin Gurney · Belmont, US
• Kenneth Hillan · San Francisco, US
• Ivar Kljavin · Lafayette, US
• Jennie P. Mather · Millbrae, US
• James Pan · Belmont, US
• Nicholas Paoni · Moraga, US
• Margaret Roy · San Francisco, US
• Timothy Stewart · San Francisco, US
• Daniel Tumas · Orinda, US
• P. Williams · Rue de l'Église, US
• William I. Wood · Hillsborough, US

Key dates

• Filing date: Jul 12, 2001
• Grant date: Jul 7, 2009
• Expiry date: Jul 12, 2021

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02P20/52
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.